METHOTREXATE SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Methotrexate Sodium, and when can generic versions of Methotrexate Sodium launch?
Methotrexate Sodium is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hikma, Hospira, Norbrook, Pharmachemie Usa, Epic Pharma Llc, Accord Hlthcare, Amneal Pharms, Barr, Daito, Duramed Pharms Barr, Eugia Pharma, Lotus Pharm Co Ltd, Mylan, Strides Pharma, Sun Pharm, Zydus Pharms, Eugia Pharma Speclts, Pharmachemie Bv, Sagent Pharms Inc, and Sandoz. and is included in thirty-seven NDAs.
The generic ingredient in METHOTREXATE SODIUM is calcium chloride; dextrose; glutathione disulfide; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate. There are two hundred and eighty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcium chloride; dextrose; glutathione disulfide; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METHOTREXATE SODIUM?
- What are the global sales for METHOTREXATE SODIUM?
- What is Average Wholesale Price for METHOTREXATE SODIUM?
Summary for METHOTREXATE SODIUM
US Patents: | 0 |
Applicants: | 22 |
NDAs: | 37 |
Finished Product Suppliers / Packagers: | 20 |
Raw Ingredient (Bulk) Api Vendors: | 40 |
Clinical Trials: | 36 |
Patent Applications: | 4,363 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in METHOTREXATE SODIUM? | METHOTREXATE SODIUM excipients list |
DailyMed Link: | METHOTREXATE SODIUM at DailyMed |
![METHOTREXATE SODIUM drug patent expirations Drug patent expirations by year for METHOTREXATE SODIUM](/p/graph/s/t/METHOTREXATE_SODIUM-patent-expirations.png)
Recent Clinical Trials for METHOTREXATE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
AstraZeneca | Phase 3 |
Seoul National University Bundang Hospital | Phase 1 |
Servier | Phase 1 |
Pharmacology for METHOTREXATE SODIUM
Drug Class | Folate Analog Metabolic Inhibitor |
Mechanism of Action | Folic Acid Metabolism Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for METHOTREXATE SODIUM
US Patents and Regulatory Information for METHOTREXATE SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | METHOTREXATE SODIUM PRESERVATIVE FREE | methotrexate sodium | INJECTABLE;INJECTION | 089343-001 | Sep 16, 1986 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Accord Hlthcare | METHOTREXATE SODIUM PRESERVATIVE FREE | methotrexate sodium | INJECTABLE;INJECTION | 040716-001 | Apr 30, 2007 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sagent Pharms Inc | METHOTREXATE SODIUM PRESERVATIVE FREE | methotrexate sodium | INJECTABLE;INJECTION | 203407-003 | Aug 9, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |